Ironwood Pharmaceuticals (IRWD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.31
- Estimate
- $0.28
- Surprise
- +12.7%
- Revenue (period 2026-06-30)
- $113.0M
- Score at report (before → after)
- 7.3 → 7.0/10
Revenue source: xbrl.
How the report landed
Ironwood Pharmaceuticals (IRWD) beat the $0.28 estimate with adjusted EPS of $0.31 — a large 12.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.3/10) to Strong Buy at 7.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRWD Buy (Wait) at 6.7/10.
2 of the last 4 quarters beat the estimate; this quarter's +12.7% surprise compares with a -57.0% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- High-quality business
- Attractive valuation
What argues against it
- Thin upside margin: 8.2%
- Elevated risk factors
- Overbought (RSI 89)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.85
- Entry target
- $4.57
- Price target
- $5.25
- Stop
- $4.25
- Upside to target
- +8.2%
- Reward-to-risk
- 0.6:1
The stock trades at 5.4× trailing but 3.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 89 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
IRWD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $799.6M
- P/E (fwd)
- 3.1
- P/E (ttm)
- 5.4
- 52-week range
- $2.95–$5.78
- Off 52-week high
- 16.1%
- RSI (14)
- 89
- Volume vs avg
- 1.26×
- Score today
- 6.7/10